GlassScriptPhysician profile
Babak Deyhimpanah
NPI 1518298918
$1,870.51
in general payments reported to CMS, 2019-2025
27 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.66 · 2020: $32.09 · 2022: $37.88 · 2024: $463 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $264.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $255.37 | 2024-2025 | |
| Novo Nordisk INC | $176.09 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $174.04 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $157.12 | 2024-2025 | Zoryve |
| Lundbeck LLC | $99.40 | 2024-2025 | Rexulti |
| Amgen INC. | $83.82 | 2024-2025 | Evenity, Prolia |
| Pfizer INC. | $66.36 | 2024-2025 | |
| Corcept Therapeutics | $65.83 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $48.57 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $46.16 | 2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $42.17 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.65 | 2024-2025 | Xifaxan |
| Becton, Dickinson and Company | $39.24 | 2025 | Bd Onclarity, Bd Veritor Plus Analyzer |
| Seqirus USA INC | $37.57 | 2024-2025 | Flucelvax, Fluad |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.46 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.57 | 2025 | Caplyta |
| Dexcom, INC. | $32.34 | 2024-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $24.94 | 2024 | Yupelri |
| Glaxosmithkline, LLC. | $24.88 | 2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $19.90 | 2022 | |
| Exact Sciences Corporation | $19.85 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $19.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.98 | 2022 | |
| Lilly USA, LLC | $17.14 | 2025 | Kisunla |
| Inspire Medical Systems, INC. | $16.92 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Deyhimpanah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.